Catalog No.S1271 Synonyms: BAY g 5421
Molecular Weight(MW): 645.6
Acarbose is an inhibitor of intestinal alpha-glucosidase, used to treat type 2 diabetes mellitus.
Purity & Quality Control
|Description||Acarbose is an inhibitor of intestinal alpha-glucosidase, used to treat type 2 diabetes mellitus.|
Acarbose reversibly inhibits intestinal alpha-glucosidases, enzymes responsible for the metabolism of complex carbohydrates into absorbable monosaccharide units.
|In vivo||Acarbose reduces the absorption of monosaccharides derived from dietary carbohydrates, which play an important role in the metabolism and toxicity of some chemical compounds. Acarbose alone potentiates carbon tetrachloride (CCl4) andacetaminophen (AP) hepatotoxicity, as evidenced by significantly increased levels of both alanine transaminase (ALT) and aspartate transaminase (AST) in the plasma of rats pretreated with acarbose.  Acarbose treatment suppresses weight gain and the development of hepatic steatosis in sqstm1 gene knockout mice. Acarbose treatment up-regulates hepatic expression of the pparalpha, ucp-2, and abca1 genes, as well as srebp1c, pparalpha, and ppargamma in adipose tissue.  Acarbose-treated rats have lower body weights at 3 months of age with unaltered food consumption, and a similar effect is seen with a high-fructose diet in the JCR:LA-corpulent rat.  Acarbose markedly improves postprandial hyperglycemia, postprandial insulin level, total cholesterol, triglyceride, and free fatty acid level in Goto-Kakizaki (GK) rats. Acarbose efficiently reduces the number of monocytes adherent to aortic endothelial layer, improves acetylcholine-dependent vasodilatation, and reduces intimal thickening of the aorta in GK rats. |
-  Martin AE, et al. Am J Health Syst Pharm, 1996, 53(19), 2277-2290.
-  Wang PY, et al. Hepatology,?999, 29(1), 161-165.
-  Okada K, et al. Hepatol Res,?009, 39(5), 490-500.
|In vitro||DMSO||100 mg/mL (154.89 mM)|
|Water||100 mg/mL (154.89 mM)|
|Ethanol||8 mg/mL (12.39 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Synonyms||BAY g 5421|
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02836704||Completed||Diabetes Mellitus Type 2||Sanofi||September 9 2016||Phase 4|
|NCT01709305||Completed||Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.||November 8 2012||Phase 4|
|NCT03349684||Recruiting||Diabetes Mellitus Type 2||Bayer||March 5 2018||Phase 3|
|NCT02315495||Completed||Type 2 Diabetes||Zilin Sun|Zhongda Hospital||April 3 2015||Phase 3|
|NCT01177384||Completed||Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.||January 25 2011||Phase 3|
|NCT02953093||Recruiting||Aging||Montefiore Medical Center||November 22 2016||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.